Academic Journal
Q1BJU International
About BJU International
BJU International is a scholarly journal published by John Wiley and Sons Inc. SCImago 2025 lists it in Q1, with an SJR of 1.368 and H-index of 182.
Coverage: 1929-1994, 1996-2026. Research categories: Urology (Q1).
Source-backed journal facts
Topics in published research
Prostate Cancer Diagnosis and Treatment; Urinary Bladder and Prostate Research; Bladder and Urothelial Cancer Treatments; Prostate Cancer Treatment and Research; Urological Disorders and Treatments; Pelvic floor disorders treatments.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Reported open-access list prices
4,770.00 USD; 3,990.00 EUR; 3,200.00 GBP
APC list prices reported by OpenAlex, which obtains this information from DOAJ. Confirm current charges, taxes, waivers and eligibility with the publisher; this is not a fee quotation.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Artificial Intelligence ( AI) ‐enhanced journal club: integrating podcasts, AI , and social media in medical education
Mohamed Abouelenein, Muhammed Arif Ibis, Molly Nichols, Azhar Khan et al.
2026-10-06 · DOI: 10.1111/bju.70479Testosterone breakthrough and outcomes during intensified therapy in metastatic hormone‐sensitive prostate cancer: the ARASENS and LATITUDE trials
Xiyue Xiao, Xudong Ni, Yufan Zhao, Xiaomeng Li et al.
2026-10-05 · DOI: 10.1111/bju.70474Gleason pattern 4 length and active surveillance eligibility in Grade Group 2–4 prostate cancer
Sean A. Fletcher, Nicholas A. Pickersgill, Nate Aiken, Melissa J. Assel et al.
2026-10-04 · DOI: 10.1111/bju.70478Global trends in urological cancers: an analysis of the global burden of disease study 2023
Hanbo Lu, Yusa Zhang, Yang Zhao, Yushi Zhang et al.
2026-10-04 · DOI: 10.1111/bju.70473Real‐world radical cystectomy use in high‐risk non‐muscle‐invasive bladder cancer: a global survey
Jose Luis Dominguez Escrig, Peter Black, Junichi Inokuchi, Girish Kulkarni et al.
2026-10-02 · DOI: 10.1111/bju.70480Sexual and relational challenges in men and women affected by prostate cancer: a Project SEXUS study
Ingrid Josefine Lundorff, Christian Graugaard, Mikkel Fode, Mikael Andersson et al.
2026-10-02 · DOI: 10.1111/bju.70475Three‐generation familial risks in early‐onset prostate cancer with maternal and paternal relatives
Kari Hemminki, Frantisek Zitricky, Kristina Sundquist, Jan Sundquist et al.
2026-10-01 · DOI: 10.1111/bju.70465The PSA test for prostate cancer screening: an abridged Cochrane review
Juan V. A. Franco, Eu Chang Hwang, Jae Hung Jung, Octavio Vaimberg et al.
2026-10-01 · DOI: 10.1111/bju.70455Towards sustainable multidisciplinary renal cancer tumour boards: redesigning the referral pathway
Bhargab Ghoshal, Sarika Nalagatla, Max Roberts, Adam Mann et al.
2026-10-01 · DOI: 10.1111/bju.70451Rezvilutamide in metastatic hormone‐sensitive prostate cancer: interpreting CHART trial evidence and clinical applicability in the European Association of Urology guidelines
Lan Mi, Sheng Li, Bin Huo
2026-09-30 · DOI: 10.1111/bju.70452Oncological and continence outcomes after nerve‐sparing robot‐assisted radical prostatectomy in selected STAMPEDE‐defined high‐risk prostate cancer
Andreia Bilé‐Silva, Prabhakar Rajan, Benjamin Lamb, Mehmet Özalevli et al.
2026-09-30 · DOI: 10.1111/bju.70460The effect of time to nephrectomy on cancer‐specific mortality in pathological T stage ( pT)1b –2 renal cancer
Michele Nicolazzini, Federico Polverino, Leonardo Quarta, Maximilian Filzmayer et al.
2026-09-29 · DOI: 10.1111/bju.70468Patient‐reported outcomes as non‐muscle‐invasive bladder cancer clinical trial endpoints
Kimberly Toumazos, Spencer Bell, Katelyn Spencer, Darrell Nakagawa et al.
2026-09-28 · DOI: 10.1111/bju.70461CT urography and urinary cytology in surveillance of endoscopically managed UTUC
Pietro Scilipoti, Raffaele La Mura, Federico Zorzi, Marie Chicaud et al.
2026-09-28 · DOI: 10.1111/bju.70469Noninvasive photoacoustic imaging maps collagen and muscle remodelling in bladder outlet obstruction
Alexander Koven, Xiaolin He, Tianzhou Zhang, Shukai Huang et al.
2026-09-27 · DOI: 10.1111/bju.70444Trial design drives outcomes: harmonising efficacy across BCG ‐unresponsive bladder carcinoma in situ trials
Daniele Robesti, Ashish M. Kamat, Guillaume Ploussard, Roberto Contieri et al.
2026-09-25 · DOI: 10.1111/bju.70463Correction to “Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ ProtecT ] study)”
2026-09-22 · DOI: 10.1111/bju.70466Impact of operative time on complications after PCNL in the elderly (aged ≥70 years): the Safety and Efficacy of Nephrolithotomy in Older patients undergoing PCNL ( SENIOR ‐ PCNL) study
Łukasz Nowak, Wojciech Krajewski, Bhaskar Somani, Tomasz Szydełko et al.
2026-09-21 · DOI: 10.1111/bju.70440From stone‐free to stone‐load reduction: a volumetric perspective on surgical and functional outcomes
Francesco Di Bello, Andres K. Kanashiro, Alejandra Bravo‐Balado, Paolo Verri et al.
2026-09-21 · DOI: 10.1111/bju.70453Reviews
Community Reviews
Version History
October 4, 2026 at 8:53 pm
September 25, 2026